Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Change in Receivables: 2011-2025

Historic Change in Receivables for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to -$1.2 million.

  • Niagen Bioscience's Change in Receivables fell 63.66% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 172.98%. This contributed to the annual value of $1.3 million for FY2024, which is 156.72% up from last year.
  • As of Q3 2025, Niagen Bioscience's Change in Receivables stood at -$1.2 million, which was down 143.15% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Change in Receivables ranged from a high of $3.8 million in Q4 2022 and a low of -$2.7 million during Q2 2023.
  • Over the past 3 years, Niagen Bioscience's median Change in Receivables value was -$348,000 (recorded in 2023), while the average stood at -$134,727.
  • Over the last 5 years, Niagen Bioscience's Change in Receivables had its largest YoY gain of 2,802.31% in 2022, and its largest YoY loss of 251.76% in 2022.
  • Over the past 5 years, Niagen Bioscience's Change in Receivables (Quarterly) stood at $130,000 in 2021, then spiked by 2,802.31% to $3.8 million in 2022, then slumped by 109.22% to -$348,000 in 2023, then plummeted by 84.48% to -$642,000 in 2024, then plummeted by 63.66% to -$1.2 million in 2025.
  • Its Change in Receivables stands at -$1.2 million for Q3 2025, versus $2.7 million for Q2 2025 and -$2.0 million for Q1 2025.